SCHEMBL8620098

SCHEMBL8620098

CN(CCCN(C)CCN1C(=O)c2cccc3cccc(c23)C1=O)CCN1C(=O)c2cccc3cccc(c23)C1=O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HEXA P06865 6/20 0.75
HEXB P07686 6/20 0.75
POLB P06746 3/20 0.71
NR1I2 O75469 1/20 0.71
AHR P35869 1/20 0.71
RAD52 P43351 1/20 0.71
RCE1 Q9Y256 1/20 0.71
LCK P06239 1/20 0.64
CYP2D6 P10635 1/20 0.58
FTO Q9C0B1 1/20 0.58
CYP1B1 Q16678 1/20 0.57
OGA O60502 1/20 0.56
SIRT1 Q96EB6 3/20 0.56
CYP3A4 P08684 1/20 0.56
NFKB1 P19838 1/20 0.56
HSD17B10 Q99714 1/20 0.56
KMT2A Q03164 2/20 0.55
MEN1 O00255 1/20 0.55
KDM4E B2RXH2 3/20 0.55
ALDH1A1 P00352 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28976576 0.95 HEXA (0.82) HEXAHEXBPOLBNR1I2AHR
SCHEMBL3292136 0.93 LCK (0.68) HEXAHEXBPOLBNR1I2AHR
SCHEMBL10396110 0.92 POLB (0.83) HEXAHEXBPOLBNR1I2AHR
SCHEMBL12672650 0.91 LCK (0.65) HEXAHEXBPOLBNR1I2AHR
SCHEMBL12660257 0.90 HEXA (0.61) HEXAHEXBPOLBNR1I2AHR
SCHEMBL14463932 0.90 LCK (0.64) HEXAHEXBPOLBNR1I2AHR
SCHEMBL12672841 0.89 LCK (0.66) HEXAHEXBPOLBNR1I2AHR
SCHEMBL14525135 0.89 HEXA (0.60) HEXAHEXBPOLBNR1I2AHR
SCHEMBL28976570 0.88 HEXA (0.71) HEXAHEXBPOLBNR1I2AHR
SCHEMBL12660389 0.88 HEXA (0.63) HEXAHEXBPOLBNR1I2AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947839-B2 Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use GENENTECH, INC. (US) 2011-05-24 US disclosed
US-20070134243-A1 Antibody drug conjugates and methods GENENTECH, INC. 2007-06-14 US disclosed
EP-0714387-B1 NEW BIS-NAPHTHALIMIDES FOR THE TREATMENT OF CANCER BASF AG (DE) 1998-05-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070134243-A1 Antibody drug conjugates and methods BOD1L1, MKI67, CCNI HEXA 3422/4885HEXB 3477/4885POLB 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.